<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896934</url>
  </required_header>
  <id_info>
    <org_study_id>130360</org_study_id>
    <secondary_id>R21MH099218-01A1</secondary_id>
    <nct_id>NCT01896934</nct_id>
  </id_info>
  <brief_title>Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression</brief_title>
  <official_title>Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term goal of this line of research is to determine if decreased vascular reactivity
      and frontal hypoperfusion is associated with poor response antidepressants. Such perfusion
      deficits could contribute to antidepressant nonresponse as they would hinder improvements in
      dorsal system metabolism seen with antidepressant treatment. The objective of the current
      proposal is to determine if decreased vascular reactivity and frontal hypoperfusion in
      depressed elders predicts and persists with antidepressant nonremission. The investigators
      will pursue the primary aim testing the hypothesis that decreased reactivity and
      hypoperfusion, specifically in the dorsolateral prefrontal cortex and dorsal anterior
      cingulate cortex, predict antidepressant nonremission. The investigators will enroll 40
      depressed elders who will complete clinical, cognitive, and MRI assessments before and after
      a 12-week open-label antidepressant trial of sertraline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term goal of this line of research is to determine if in late-life depression (LLD),
      cerebrovascular dysregulation is predictive of antidepressant outcomes. The investigators
      hypothesize that vascular pathology resulting in reduced cerebrovascular reactivity
      contributes to frontocingulate hypoperfusion. Such pathology would impair neurovascular
      coupling and reduce the ability of the vasculature to improve frontocingulate perfusion
      during antidepressant treatment. Thus decreased cerebrovascular reactivity and perfusion may
      be a biomarker of antidepressant nonresponse. As an initial step in this research, the
      current study will utilize MRI arterial spin labeling (ASL) to examine if cerebrovascular
      reactivity deficits and resting cerebral blood flow (CBF) deficits predict antidepressant
      nonremission in LLD. The rationale for this proposal is that it will identify mechanisms by
      which vascular pathology may contribute to LLD. If the study hypotheses are correct, this
      crucial next step will support studies examining antidepressant properties of cardiovascular
      drugs that may reverse vascular pathology and improve perfusion.

      The investigators will pursue our initial goal by examining ASL predictors of nonremission to
      a 12-week trial of sertraline. Forty LLD subjects will complete MRI, cognitive testing, and
      hyperintensity assessment. ASL measured CBF will be obtained during a hypercapnia challenge
      and at rest with room air. This will help determine if deficits in cerebrovascular reactivity
      (CVR) and/or resting and on-demand CBF measures predict nonremission.

      AIM: To test for differences in CVR and CBF in dorsal frontal cognitive control regions
      between individuals who do and do not remit to a 12-week course of sertraline (defined as
      MADRS ≤ 7).

      Hypothesis 1: Compared with remitters, during a hypercapnia challenge nonremitters will
      exhibit less CVR in the dlPFC and dAC.

      Hypothesis 2: Compared with remitters, while breathing room air nonremitters will exhibit
      lower resting CBF in the dorsal anterior cingulate (dAC) and dorsolateral prefrontal cortex
      (dlPFC).

      Exploratory Aim: To examine the relationship between ASL measures (CVR to hypercapnia and
      resting CBF during normoxia) and performance in cognitive domains implicated in LLD treatment
      outcomes. For this Aim, we will focus on functions involving the dlPFC and dAC, specifically
      executive function and processing speed.

      The study will enroll patients from clinical referrals and response to advertisements. In
      these cases, potential participants will call our study contact number. Study staff will
      describe the study to them, including a description of the study entry criteria. Those who
      continue to be interested will then be scheduled for an evaluation. After scheduling, a study
      physician will review their electronic medical record to assure that potential subjects meet
      entry criteria.

      Following policies of the Vanderbilt University Health System Institutional Review Board,
      written informed consent will be obtained and documented by the study's Research Coordinator
      before any study-related procedures are performed. The study coordinator will review study
      procedures and the consent form with each potential participant. Each individual may take as
      much time as they like to decide if they do or do not wish to participate. There is no
      randomization. All participants receive open-label sertraline.

      An initial evaluation will determine eligibility, depression severity, and evaluate medical
      and psychiatric history. Participants will also complete a detailed battery assessing
      cognitive function. During this time they will also complete the one-hour MRI session, which
      includes measurement of cerebral perfusion and vascular reactivity.

      They will then begin the 12-week trial of open-label sertraline, allowing titration up to the
      maximum dose of 200mg daily. At the end of the study participants will be referred for
      ongoing clinical treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of Depression</measure>
    <time_frame>Week 12</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS) is a measure of depression severity. This will be used to define remission as a score of 7 or less.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinician-rated Depression Severity</measure>
    <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
    <description>Change in depression severity will be measured by the clinician-rated Montgomery Asberg Depression Rating Scale (MADRS), range of 0-60, with higher scores indicating more severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-rated Depression Severity</measure>
    <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
    <description>Change in depression severity measured by the patient-rated Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16). The QIDS-SR16 is a self-report measure of depression severity with a range of 0-27, with higher scores indicative of more severe depression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50-200mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50-200mg daily</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 60 years or older.

          2. Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent
             or chronic, without psychotic features, as detected by MINI and clinical exam.

          3. Minimum MADRS score ≥ 15.

          4. Mini-Mental State Exam ≥ 22.

          5. Ability to read and write English.

        Exclusion Criteria:

          1. Current or past diagnoses of other Axis I psychiatric disorders, including panic
             disorder and substance dependence.

          2. Any use of illicit substances (such as marijuana or cocaine) or abuse of prescription
             medications (such as benzodiazepines or opiates) within the last three months.

          3. Presence of acute suicidality

          4. Current or past psychosis

          5. Known primary neurological disorder, including dementia, brain tumors, epilepsy,
             Parkinson's disease, or demyelinating diseases

          6. Chronic untreated medical disorders (including but not limited to hypertension,
             hyperlipidemia, fibromyalgia, hypothyroidism, or any other disorder) where treatment
             is warranted

          7. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge
             would be contraindicated or put the subject at increased risk. This would include
             active respiratory disease, chronic angina or other unstable cardiac conditions.

          8. Any physical or intellectual disability affecting completion of assessments

          9. MRI contraindications

         10. Electroconvulsive therapy in last 6 months

         11. Use of fluoxetine in the last 6 weeks. Occasional use of benzodiazepines or
             non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during the
             last month is allowable.

         12. Known allergy or hypersensitivity to sertraline

         13. A failed therapeutic trial of sertraline in the current depressive episode (defined as
             at least 6 weeks of treatment at a daily dose of 100mg or higher)

         14. Current or planned psychotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren D Taylor, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>May 16, 2017</results_first_submitted>
  <results_first_submitted_qc>June 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2017</results_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Warren Taylor</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Antidepressants</keyword>
  <keyword>Elderly</keyword>
  <keyword>Geriatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants taking ineffective antidepressant medications underwent a washout period. 10 recruited individuals were withdrawn after screening for a) concomitant medications (N=2), b) depression not severe (N=4), c) MRI contraindications (N=4)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sertraline</title>
          <description>50-200mg daily
Sertraline: 50-200mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline</title>
          <description>50-200mg daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.05" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale</title>
          <description>Depression rating scale, clinician rated, range 0-60, where higher scores indicate more severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.43" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quick Inventory of Depressive Symptoms</title>
          <description>Depression rating scale, self-report, Range 0-27, where higher scores indicate more severe depression</description>
          <population>Baseline data missing for 4 individuals (3 subject did not complete, 1 deviation where questionnaire was not provided to subject)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.94" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission of Depression</title>
        <description>Montgomery-Asberg Depression Rating Scale (MADRS) is a measure of depression severity. This will be used to define remission as a score of 7 or less.</description>
        <time_frame>Week 12</time_frame>
        <population>Individuals achieving remission of depression, defined as MADRS score of 7 or less.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>50-200mg daily
Sertraline: 50-200mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Remission of Depression</title>
          <description>Montgomery-Asberg Depression Rating Scale (MADRS) is a measure of depression severity. This will be used to define remission as a score of 7 or less.</description>
          <population>Individuals achieving remission of depression, defined as MADRS score of 7 or less.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinician-rated Depression Severity</title>
        <description>Change in depression severity will be measured by the clinician-rated Montgomery Asberg Depression Rating Scale (MADRS), range of 0-60, with higher scores indicating more severe depression</description>
        <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>50-200mg daily
Sertraline: 50-200mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinician-rated Depression Severity</title>
          <description>Change in depression severity will be measured by the clinician-rated Montgomery Asberg Depression Rating Scale (MADRS), range of 0-60, with higher scores indicating more severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.14" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-rated Depression Severity</title>
        <description>Change in depression severity measured by the patient-rated Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16). The QIDS-SR16 is a self-report measure of depression severity with a range of 0-27, with higher scores indicative of more severe depression.</description>
        <time_frame>Assessed every 2 weeks from baseline to week 12, change from baseline to week 12 is reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>50-200mg daily
Sertraline: 50-200mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-rated Depression Severity</title>
          <description>Change in depression severity measured by the patient-rated Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16). The QIDS-SR16 is a self-report measure of depression severity with a range of 0-27, with higher scores indicative of more severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Adverse events and serious adverse event definitions are concordant with clinicaltrials.gov definitions.
Adverse events were assessed at every contact by asking individuals about any medical problems or potential side effects they were experiencing.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sertraline</title>
          <description>50-200mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include a small sample that reflects this is a pharmacoimaging study using MRI to examine imaging findings related to antidepressant treatment outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Warren D Taylor</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-936-3555</phone>
      <email>warren.d.taylor@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

